Protara Therapeutics Inc expected to post a loss of 98 cents a share - Earnings Preview

Protara Therapeutics

30/10/2023 14:14

* Protara Therapeutics Inc  TARA.OQ   TARA.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Protara
Therapeutics Inc
is for a loss of 98 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protara
Therapeutics Inc is $30​, above​ its last closing price
of $1.21. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.88       -0.87      -1.00     Missed  -14.3
 Mar. 31 2023  -0.91       -0.88      -0.80     Beat    8.8
 Dec. 31 2022              -0.75      -1.55     Missed  -106.7
                                                        ​
 Sep. 30 2022  -0.77       -0.76      -0.68     Beat    10.1
 ​​Jun.        -1.02       -0.94      -0.80     Beat    14.6
 30 2022                                                
 Mar. 31 2022  -1.01       -0.90      -0.96     Missed  -6.3​
 Dec. 31 2021              -0.94      -0.91     Beat    3.5
 Sep. 30 2021  -1.11       -1.01      -0.96     Beat    5
 This summary was machine generated October 30 at 14:14 GMT.  All
figures in US dollars  unless otherwise stated